发明授权
US07557111B2 Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
失效
取代的噻吩并[3,2-d]嘧啶作为CRF受体拮抗剂
![Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists](/docs/US/2009-07-07/US07557111B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
- 专利标题（中）： 取代的噻吩并[3,2-d]嘧啶作为CRF受体拮抗剂
-
申请号： US10584951申请日： 2005-01-06
-
公开(公告)号： US07557111B2公开(公告)日： 2009-07-07
- 发明人: Atsuro Nakazato , Taketoshi Okubo , Dai Nozawa , Tomoko Tamita , Ludo E. J. Kennis
- 申请人： Atsuro Nakazato , Taketoshi Okubo , Dai Nozawa , Tomoko Tamita , Ludo E. J. Kennis
- 申请人地址： JP Tokyo
- 专利权人： Taisho Pharmaceutical Co., Ltd.
- 当前专利权人： Taisho Pharmaceutical Co., Ltd.
- 当前专利权人地址： JP Tokyo
- 代理机构： Sughrue Mion, PLLC
- 优先权： JP2004-001310 20040106
- 国际申请： PCT/JP2005/000318 WO 20050106
- 国际公布： WO2005/066182 WO 20050721
- 主分类号： C07D495/04
- IPC分类号： C07D495/04 ; A61K31/519
![Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists](/abs-image/US/2009/07/07/US07557111B2/abs.jpg.150x150.jpg)
摘要：
An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
公开/授权文献
信息查询
